Repare Therapeutics (RPTX) announced a cooperative research and development agreement, or CRADA, has been executed to advance the development of camonsertib as an anticancer agent in collaboration with the Cancer Therapy Evaluation Program, or CTEP, of the US National Cancer Institute, part of the US National Institutes of Health.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RPTX:
- Repare Therapeutics Reports Q3 2024 Progress and Outlook
- Repare Therapeutics reports Q3 EPS (81c), consensus (83c)
- Repare Therapeutics presents data from Phase 1 MYTHIC clinical trial
- Repare Therapeutics doses first patient in POLAR trial
- Repare Therapeutics reports ‘encouraging’ Phase 1 camonsertib combo data
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
